HPC8
MCID: PRS130
MIFTS: 33

Prostate Cancer, Hereditary, 8 (HPC8)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 8

MalaCards integrated aliases for Prostate Cancer, Hereditary, 8:

Name: Prostate Cancer, Hereditary, 8 57
Predisposing for Prostate Cancer 57 13
Predisposing for Prostate Cancer; Pcap 57
Prostate Cancer, Susceptibility to 57
Prostate Cancer 57
Hpc8 57
Pcap 57

Classifications:



External Ids:

OMIM 57 602759
MedGen 42 C1864472

Summaries for Prostate Cancer, Hereditary, 8

MalaCards based summary : Prostate Cancer, Hereditary, 8, also known as predisposing for prostate cancer, is related to prostate cancer and prostate cancer, hereditary, 1. An important gene associated with Prostate Cancer, Hereditary, 8 is PCAP (Predisposing For Prostate Cancer). The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast.

More information from OMIM: 602759

Related Diseases for Prostate Cancer, Hereditary, 8

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1181)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 13.2
2 prostate cancer, hereditary, 1 12.8
3 prostate cancer, hereditary, 2 12.8
4 prostate cancer, hereditary, 13 12.7
5 prostate cancer, hereditary, 12 12.7
6 prostate cancer, hereditary, 11 12.7
7 prostate cancer, hereditary, 4 12.7
8 prostate cancer, hereditary, 3 12.5
9 prostate cancer, hereditary, 6 12.5
10 prostate cancer, hereditary, x-linked 1 12.5
11 prostate cancer/brain cancer susceptibility 12.5
12 prostate cancer, hereditary, 9 12.5
13 prostate cancer, hereditary, 7 12.5
14 prostate cancer, hereditary, 10 12.4
15 prostate cancer, hereditary, 15 12.4
16 prostate cancer, hereditary, 14 12.4
17 prostate cancer, hereditary, x-linked 2 12.4
18 prostate cancer, hereditary, 5 12.4
19 prostate cancer aggressiveness quantitative trait locus on chromosome 19 12.3
20 prostate disease 11.7
21 radiation proctitis 11.6
22 alopecia, androgenetic, 1 11.5
23 hereditary breast ovarian cancer syndrome 11.5
24 brca2 hereditary breast and ovarian cancer syndrome 11.5
25 gastric cancer, hereditary diffuse 11.5
26 prostate sarcoma 11.5
27 pachyonychia congenita 3 11.4
28 diethylstilbestrol syndrome 11.3
29 prostatic hypertrophy 11.3
30 prostatic hyperplasia, benign 11.3
31 prostatic adenoma 11.3
32 brca1 hereditary breast and ovarian cancer syndrome 11.2
33 impotence 11.1
34 suppression of tumorigenicity 12 11.1
35 colorectal adenoma 11.0
36 adenocarcinoma 11.0
37 chronic interstitial cystitis 11.0
38 neutropenia 10.9
39 severe combined immunodeficiency 10.9
40 prostatitis 10.9
41 bladder cancer 10.9
42 sexual disorder 10.8
43 bone disease 10.8
44 bone resorption disease 10.8
45 proctitis 10.8
46 insulin-like growth factor i 10.8
47 body mass index quantitative trait locus 1 10.7
48 breast cancer 10.7
49 osteoporosis 10.7
50 bone mineral density quantitative trait locus 8 10.7

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 8:



Diseases related to Prostate Cancer, Hereditary, 8

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 8

Clinical features from OMIM:

602759

Drugs & Therapeutics for Prostate Cancer, Hereditary, 8

Drugs for Prostate Cancer, Hereditary, 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 863)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
7
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Desflurane Approved Phase 4 57041-67-5 42113
10
Ondansetron Approved Phase 4 99614-02-5 4595
11
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
12
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
13
Chlorpheniramine Approved Phase 4 132-22-9, 113-92-8 2725
14
Fosfomycin Approved Phase 4 23155-02-4 446987
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Pasireotide Approved Phase 4 396091-73-9 9941444
17
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
18
Polyestradiol phosphate Approved Phase 4 28014-46-2
19
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
20
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
21
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
22
Cabergoline Approved Phase 4 81409-90-7 54746
23
Zoledronic Acid Approved Phase 4 118072-93-8 68740
24
tannic acid Approved Phase 4 1401-55-4
25
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
26
Denosumab Approved Phase 4 615258-40-7
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
33
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
34
Pamidronate Approved Phase 4 40391-99-9 4674
35
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
36
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
37
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
38
4-Aminopyridine Approved Phase 4 504-24-5 1727
39
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
40
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
41
Testosterone enanthate Approved Phase 4 315-37-7 9416
42
Methyltestosterone Approved Phase 4 58-18-4 6010
43
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
45
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
46
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
47
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
48
Genistein Investigational Phase 4 446-72-0 5280961
49
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
50 Phytoestrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 4547)
# Name Status NCT ID Phase Drugs
1 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer Unknown status NCT01352598 Phase 4
3 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
4 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
5 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
7 To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial Unknown status NCT02744937 Phase 4 Aspirin
8 Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Unknown status NCT01770340 Phase 4
9 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
10 The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
11 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
12 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
13 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
14 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
15 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
16 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
17 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
18 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
19 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
20 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
21 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
22 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
23 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
24 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
25 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
26 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo
27 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
28 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
29 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
30 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
31 A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
32 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
33 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
34 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
35 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
36 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
37 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
38 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
39 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
40 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
41 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
42 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
43 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
44 A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy Completed NCT00953277 Phase 4
45 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
46 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
47 The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
48 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
49 A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
50 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)

Search NIH Clinical Center for Prostate Cancer, Hereditary, 8

Genetic Tests for Prostate Cancer, Hereditary, 8

Anatomical Context for Prostate Cancer, Hereditary, 8

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 8:

41
Prostate, Bone, Breast, Lung, Testes, Lymph Node, T Cells

Publications for Prostate Cancer, Hereditary, 8

Articles related to Prostate Cancer, Hereditary, 8:

# Title Authors PMID Year
1
PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. 8
11313747 2001
2
Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. 8
10090894 1999
3
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. 8
9585607 1998
4
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. 8
8910276 1996
5
[Hereditary prostate cancer]. 38
15510898 2004
6
Heterogeneity in genetic susceptibility to prostate cancer. 38
11173005 2001

Variations for Prostate Cancer, Hereditary, 8

Expression for Prostate Cancer, Hereditary, 8

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 8.

Pathways for Prostate Cancer, Hereditary, 8

GO Terms for Prostate Cancer, Hereditary, 8

Sources for Prostate Cancer, Hereditary, 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....